Abstract

Mirzagolib Tillyashayhov* and Uktam Eshmuradov

ABSTRACT

Breast cancer is the leading cause of cancer mortality worldwide.[1] Approximately 50% of all women with breast cancer develop metastases to distant organs, such as the liver, lungs, bones and brain.[2,3] Liver metastases develop in about 50% of all patients with metastatic breast cancer, and in 5-12% of patients liver metastases are the primary site of damage in breast cancer.[4] Metastatic liver damage can cause severe liver dysfunction, which negatively affects the prognosis of breast cancer patients. In the absence of treatment, liver metastases are associated with poor survival and range from 4 to 8 months.[5,6,7] In addition, despite the improvement of systemic treatment, the average life expectancy of patients with metastatic liver damage from the moment of diagnosis varies from 18 to 24 months, and 5-year and 10-year survival is still low - 27% and 13%, respectively.[8,9,10] In this connection, only a personalized approach to the treatment of liver metastases, based on the category of disease prognosis, determines the relevance of this study.